Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Inhaleerbare therapie tegen longkanker
mei 2024 | Longoncologie
dec 2023 | Uro-oncologie
dec 2022 | Maag-darm-leveroncologie
okt 2021 | Uro-oncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
mrt 2024
nov 2023
sep 2023